. Author manuscript; available in PMC: 2014 Jan 21.

Published in final edited form as: J Pharmacokinet Pharmacodyn. 2013 Jan 12;40(2):157–176. doi: 10.1007/s10928-012-9295-8

Table 8.

Single dose lapatinib observed and predicted human half-life (t_1/2), maximum concentration (C_max) and time of maximum concentration (T_max)

Dose (mg)	Observed t_1/2 (h)	Predicted t_1/2 (h)	T_1/2 PE%^c	Observed C_max (nM)	Predicted C_max (nM)	C_max PE%^c	Observed T_max (h)	Predicted T_max (h)	T_max PE%^c	Reference
50	6.0^a (4.8–7.5)	10.0	66.7	124 (88–177)^d	66	−46.7	3.0 (2.0–6.0)^f	3.75	25.0	[4]
100	6.3^a (5.6–7.0)	10.0	58.7	213 (148–308)^d	132	−38.1	4.0 (2.5–5.9)^f	3.75	−6.3	[4]
100	9.6^a (8.5–10.7)	10.0	4.2	198 (174–224)^e	132	−33.3	4.0 (2.5–8.0)^f	3.75	−6.3	[14]
175	8.2^a (6.7–9.9)	10.0	22.0	380 (241–599)^d	231	−39.3	3.0 (2.0–4.0)^f	3.75	25.0	[4]
250	8.8^a (6.6–11.7)	10.0	13.6	546 (330–902)^d	329	−39.7	4.0 (3.0–6.0)^f	3.75	−6.3	[4]
250	10.2^a (9.24–11.3)	10.0	−2.0	449 (360–563)^e	329	−26.8	4.0 (2.5–6.0)^f	3.75	−6.3	[14]
900	12.9^b (10.1–18.3)	10.0	−22.5	1,740 (1,194–2,533)^d	1,185	−31.9	4.0 (2.0–6.0)^g	3.75	−6.3	[13]
1,200	11.5^b (10.1–19.5)	10.0	−13.0	1,767 (816–3,833)^d	1,581	−10.5	3.5 (2.1–6.0)^g	3.75	7.1	[13]
1,600	13.9^b (9.6–18.0)	10.0	−28.1	2,647 (1,793–3,903)^d	2,107	−20.4	4.0 (2.0–8.0)^g	3.75	−6.3	[13]
1,800	15.7^b (11.0–133.1)	10.0	−36.3	2,112 (800–5,579)^d	2,371	12.3	3.9 (3.0–8.0)^g	3.75	−3.8	[13]

t_1/2 is the terminal half-life geometric mean (95 % confidence interval)

t_1/2 is the terminal half-life median (95 % confidence interval)

PE% is the prediction error

Is the geometric mean (95 % confidence interval) of C_max

Is the geometric mean (range) of C_max

Is the median (range) of T_max

Is the median (95 % confidence interval) of T_max